Plasma Lipoprotein-associated Phospholipase A2 Is Inversely Correlated with Proprotein Convertase Subtilisin-kexin Type 9

被引:18
|
作者
Constantinides, Alexander [1 ,2 ]
Kappelle, Paul J. W. H. [1 ,2 ]
Lambert, Gilles [3 ,4 ]
Dullaart, Robin P. F. [1 ,2 ]
机构
[1] Univ Med Ctr Groningen, Dept Endocrinol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Groningen, Netherlands
[3] Heart Res Inst, Sydney, NSW, Australia
[4] Fac Med, Lab Inserm U957, Nantes, France
关键词
Low-density lipoprotein cholesterol; Lp-PLA(2); PCSK9; PCSK9; DISEASE; RISK;
D O I
10.1016/j.arcmed.2012.01.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and Aims. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a proatherogenic phospholipase A(2), which is predominantly complexed to low-density lipoprotein (LDL) particles. Proprotein convertase subtilisin-kexin type 9 (PCSK9) provides a key step in LDL metabolism by stimulating LDL receptor degradation. We determined relationships between plasma PCSK9 and Lp-PLA(2) mass. Methods. Lp-PLA(2) mass (turbidimetric immunoassay), PCSK9 (enzyme-linked immunosorbent assay) and (apo) lipoproteins were measured in 53 nondiabetic subjects (27 women) with body mass index <30 kg/m(2). Results. Lp-PLA(2) and PCSK9 levels were both correlated positively with LDL cholesterol and non-high-density lipoprotein (HDL) cholesterol (r = 0.330 to r = 0.382, p <= 0.02). Remarkably, Lp-PLA(2) was inversely related to PCSK9 (r = -0.388, p = 0.004). The Lp-PLA(2)/apolipoprotein B ratio, as a measure of the Lp-PLA(2) content in apolipoprotein B-containing lipoproteins, was also inversely correlated with PCSK9 (r = -0.575, p <0.001). The inverse relationships of Lp-PLA(2) (p = 0.023) and the Lp-PLA(2)/apolipoprotein B ratio (p = 0.001) with PCSK9 levels remained significant after controlling for age, gender, triglycerides and HDL cholesterol. Conclusions. Despite increasing effects on LDL cholesterol, higher PCSK9 levels are unlikely to confer impaired Lp-PLA(2) metabolism. We propose to evaluate the possible influence of PCSK9 inhibiting strategies on Lp-PLA(2) regulation and vice versa to determine effects of Lp-PLA(2) inhibitors on the PCSK9 pathway. (C) 2012 IMSS. Published by Elsevier Inc.
引用
收藏
页码:11 / 14
页数:4
相关论文
共 50 条
  • [21] Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
    Baragetti, Andrea
    Grejtakova, Daniela
    Casula, Manuela
    Olmastroni, Elena
    Jotti, Gloria Saccani
    Norata, Giuseppe Danilo
    Catapano, Alberico L.
    Bellosta, Stefano
    PHARMACOLOGICAL RESEARCH, 2018, 130 : 1 - 11
  • [22] Plasma eicosanoid profiling in the course of proprotein convertase subtilisin-kexin type 9 inhibition: insights from a metabolomic analysis
    Schrutka, L.
    Hagn, G.
    Galli, L.
    Poeschl, A.
    Seidl, V.
    Ondracek, A.
    Bileck, A.
    Lang, I.
    Hengstenberg, C.
    Krychtiuk, K.
    Speidl, W.
    Gerner, C.
    Distelmaier, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 3031 - 3031
  • [23] Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects
    Kappelle, Paul J. W. H.
    Lambert, Gilles
    Dahlback, Bjorn
    Nielsen, Lars Bo
    Dullaart, Robin P. F.
    ATHEROSCLEROSIS, 2011, 214 (02) : 492 - 494
  • [24] LIPOPROTEIN(A) AND PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN A REPRESENTATIVE SAMPLE OF YOUNG MALES
    Benimetskaya, K.
    Yachmeneva, M.
    Shcherbakova, L.
    Denisova, D.
    Ragino, Y.
    ATHEROSCLEROSIS, 2020, 315 : E146 - E146
  • [25] Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery
    Liberopoulos, Evangelos
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) : 813 - 815
  • [26] Statins Induce Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9
    Lagace, Thomas A.
    Bashmakov, Yuriy
    Anderson, Norma N.
    McNutt, Markey C.
    Grefhorst, Aldo
    Ho, Y. K.
    Horton, Jay D.
    FASEB JOURNAL, 2008, 22
  • [27] Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels: modification by adiposity in nondiabetic subjects
    Kappelle, P. J. W. H.
    Lambert, G.
    Dahlback, B.
    Nielsen, L. B.
    Dullaart, R. P. F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 : 61 - 61
  • [28] Plasma eicosanoid profiling in the course of proprotein convertase Subtilisin-Kexin type 9 inhibition: Insights from a metabolomic analysis
    Schrutka, L.
    Hagn, G.
    Galli, L.
    Poeschl, A.
    Seidl, V
    Ondracek, A. S.
    Bileck, A.
    Lang, I
    Hengstenberg, C.
    Krychtiuk, K.
    Speidl, W.
    Gerner, C.
    Distelmaier, K.
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 2) : 160 - 161
  • [29] The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
    Grobelna, Malwina K.
    Strauss, Ewa
    Krasinski, Zbigniew
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 16 (03) : 128 - 132
  • [30] Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk
    Martinez, Laurent O.
    Perret, Bertrand
    Genoux, Annelise
    CURRENT OPINION IN LIPIDOLOGY, 2021, 32 (05) : 324 - 327